HRAS is an inclusion criterion in 26 clinical trials for malignant solid tumor, of which 18 are open and 8 are closed. Of the trials that contain HRAS status and malignant solid tumor as inclusion criteria, 15 are phase 1 (10 open), 4 are phase 1/phase 2 (2 open), and 7 are phase 2 (6 open) [4].

HRAS is an inclusion criterion in 16 clinical trials for colorectal carcinoma, of which 12 are open and 4 are closed. Of the trials that contain HRAS status and colorectal carcinoma as inclusion criteria, 10 are phase 1 (8 open), 3 are phase 1/phase 2 (2 open), and 3 are phase 2 (2 open) [4].

HRAS is an inclusion criterion in 15 clinical trials for non-small cell lung carcinoma, of which 11 are open and 4 are closed. Of the trials that contain HRAS status and non-small cell lung carcinoma as inclusion criteria, 10 are phase 1 (8 open), 2 are phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [4].

HRAS is an inclusion criterion in 9 clinical trials for melanoma, of which 7 are open and 2 are closed. Of the trials that contain HRAS status and melanoma as inclusion criteria, 6 are phase 1 (4 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 8 clinical trials for acute myeloid leukemia, of which 6 are open and 2 are closed. Of the trials that contain HRAS status and acute myeloid leukemia as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [4].

HRAS is an inclusion criterion in 7 clinical trials for myelodysplastic syndromes, of which 5 are open and 2 are closed. Of the trials that contain HRAS status and myelodysplastic syndromes as inclusion criteria, 1 is early phase 1 (1 open), 3 are phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [4].

HRAS is an inclusion criterion in 5 clinical trials for chronic myelomonocytic leukemia, of which 4 are open and 1 is closed. Of the trials that contain HRAS status and chronic myelomonocytic leukemia as inclusion criteria, 2 are phase 1/phase 2 (1 open) and 3 are phase 2 (3 open) [4].

HRAS is an inclusion criterion in 5 clinical trials for non-hodgkin lymphoma, of which 3 are open and 2 are closed. Of the trials that contain HRAS status and non-hodgkin lymphoma as inclusion criteria, 1 is early phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 3 are phase 2 (2 open) [4].

HRAS is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain HRAS status and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 2 are open and 1 is closed. Of the trials that contain HRAS status and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 3 clinical trials for squamous cell lung carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and squamous cell lung carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 3 clinical trials for thyroid gland carcinoma, of which 3 are open and 0 are closed. Of the trials that contain HRAS status and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for acute lymphoblastic leukemia, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and acute lymphoblastic leukemia as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain HRAS status and cancer as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for glioma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for histiocytic and dendritic cell neoplasm, of which 1 is open and 1 is closed. Of the trials that contain HRAS status and histiocytic and dendritic cell neoplasm as inclusion criteria, 2 are phase 2 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for low grade glioma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and low grade glioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for multiple myeloma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and multiple myeloma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for neurofibromatosis type 1, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and neurofibromatosis type 1 as inclusion criteria, 2 are phase 2 (2 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and pancreatic carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain HRAS status and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for poorly differentiated thyroid gland carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and poorly differentiated thyroid gland carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for small cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain HRAS status and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 2 clinical trials for squamous cell carcinoma, of which 0 are open and 2 are closed. Of the trials that contain HRAS status and squamous cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (0 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for astrocytic tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and astrocytic tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and breast carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and cholangiocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and colorectal adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for cutaneous melanoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and cutaneous melanoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and diffuse glioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and diffuse large B-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and double-hit lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for dysembryoplastic neuroepithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and dysembryoplastic neuroepithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for embryonal rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and embryonal rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and esophageal carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for gangliocytoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and gangliocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for ganglioglioma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and ganglioglioma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for low-grade neuroepithelial tumor, NOS, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and low-grade neuroepithelial tumor, NOS as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for lung adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for malignant thyroid gland neoplasm, of which 0 are open and 1 is closed. Of the trial that contains HRAS status and malignant thyroid gland neoplasm as inclusion criteria, 1 is phase 2 (0 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and mantle cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for myelodysplastic syndrome with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and myelodysplastic syndrome with excess blasts-2 as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and myeloid neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and neuroblastoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for neuronal and mixed neuronal-glial tumors, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and neuronal and mixed neuronal-glial tumors as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for pancreatic adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and peripheral T-cell lymphoma as inclusion criteria, 1 is early phase 1 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for pilocytic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and pilocytic astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for pilomyxoid astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and pilomyxoid astrocytoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 0 are open and 1 is closed. Of the trial that contains HRAS status and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and renal cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for thyroid gland undifferentiated (anaplastic) carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and thyroid gland undifferentiated (anaplastic) carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

HRAS is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].